Which immunophenotype studies do the NCCN guidelines consider as essential for the workup of non-Hodgkin lymphoma (NHL)?

Updated: Jun 12, 2019
  • Author: Priyank P Patel, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

The NCCN guidelines list the following immunophenotype studies as essential for diagnosis of non-Hodgkin lymphoma:

  • For B-cell lymphoma, an imunohistochemistry (IHC) panel including CD20, CD3, CD5, CD10, BCL2, BCL6, CD21, or CD23, with or without cell surface marker analysis by flow cytometry of kappa/lambda, CD19, CD20, CD5, CD23, CD10 [1]
  • For T-cell lymphoma, the IHC panel may include CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, CD4, CD8, CD7, CD56, CD21, CD23, EBER-ISH, TCRbeta, TCRdelta, PD1/CD279, and ALK, with or without cell surface marker analysis by flow cytometry that may include kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2; TCRalpha, TCRbeta, and TCRgam [2]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!